1:30 PM SIGN-IN • 2:00 PM - 3:30 PM

BANDOL 2 (NEW WYNN SPACE)

CE: Updates in Myelofibrosis: The Significance of JAK Inhibitors in Therapy

Myelofibrosis is a rare blood cancer with a high rate of mortality within several years of diagnosis. The identification of the certain mutations, including JAK2, CALR, and MPL, has helped to open the treatment landscape to targeted therapies. JAK (Janus-associated kinase) inhibitors are changing the therapeutic landscape from traditional chemotherapy for symptom control and agents to address anemia, and are showing that by stemming disease progression, patients’ lives may be extended. This program will focus on evidence and nuances to available JAK inhibitors and discuss agents in the pipeline for myelofibrosis. Additionally, cumulative direct and indirect costs associated with myelofibrosis and its acute impact on patients’ quality of life will be addressed.

Speakers

Julianne Darling

Jeffrey Reichard

Asembia

200 Park Avenue, Suite 300 
Florham Park, NJ 07932

973.564.8004

asembia.com

info@asembiasummit.com

SIGN UP FOR SUMMIT UPDATES

Asembia's Specialty Pharmacy Summit is a PRIVATE EVENT. Asembia reserves the right to deny registration and refuse access at our absolute and sole discretion for any reason whatsoever.

Virtual Experience Terms & Conditions

© 2020 Asembia Specialty Pharmacy Summit, LLC. All rights reserved.

CONNECT WITH US

  • Asembia LinkedIn
  • Asembia Twitter
  • Asembia Instagram
  • Asembia Facebook
  • Asembia Videos
  • Asembia Photos
SummitLogo_2020_White.png